Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib
Jamie O. Brett(Harvard University), Seth A. Wander(Harvard University), Siobhan Dunne(Texas Oncology), Azadeh Nasrazadani(The University of Texas MD Anderson Cancer Center), Laura M. Spring(Massachusetts General Hospital), Andrzej Niemierko(Harvard University), Taronish D. Dubash(Harvard University), Aditya Bardia(UCLA Health), X. Cynthia(Washington University in St. Louis), Daniel A. Haber(Howard Hughes Medical Institute), Adam Brufsky(University of Pittsburgh), Dante Che(Harvard University), Veronica Mariotti(Moffitt Cancer Center), Kevin Kalinsky(Emory University), A. John Iafrate(Massachusetts General Hospital), Hyo S. Han(Moffitt Cancer Center), Maxwell R. Lloyd(Beth Israel Deaconess Medical Center), Leslie SL Kim(Texas Oncology), Shyamala Maheswaran(Massachusetts General Hospital), Joyce O’Shaughnessy(Baylor University Medical Center), Maristela L. Onozato(Harvard University), Douglas S. Micalizzi(Massachusetts General Hospital), Jing Xi(Washington University in St. Louis), Apurva Pandey(University of Pittsburgh Medical Center)
Cited by 1